HUT65766A - Process for preparing 5-heteroyl-indole derivatives and pharmaceutical compositions containing them - Google Patents

Process for preparing 5-heteroyl-indole derivatives and pharmaceutical compositions containing them Download PDF

Info

Publication number
HUT65766A
HUT65766A HU9302328A HU9302328A HUT65766A HU T65766 A HUT65766 A HU T65766A HU 9302328 A HU9302328 A HU 9302328A HU 9302328 A HU9302328 A HU 9302328A HU T65766 A HUT65766 A HU T65766A
Authority
HU
Hungary
Prior art keywords
formula
indol
thiazole
compound
hydrogen
Prior art date
Application number
HU9302328A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9302328D0 (en
Inventor
Jolanta Teresa Nowakowski
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HU9302328D0 publication Critical patent/HU9302328D0/hu
Publication of HUT65766A publication Critical patent/HUT65766A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HU9302328A 1991-02-12 1992-02-03 Process for preparing 5-heteroyl-indole derivatives and pharmaceutical compositions containing them HUT65766A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12

Publications (2)

Publication Number Publication Date
HU9302328D0 HU9302328D0 (en) 1993-10-28
HUT65766A true HUT65766A (en) 1994-07-28

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9302328A HUT65766A (en) 1991-02-12 1992-02-03 Process for preparing 5-heteroyl-indole derivatives and pharmaceutical compositions containing them

Country Status (24)

Country Link
EP (1) EP0571471B1 (enExample)
JP (1) JPH07121942B2 (enExample)
KR (1) KR930703305A (enExample)
AT (1) ATE135005T1 (enExample)
AU (1) AU655456B2 (enExample)
CA (1) CA2101521A1 (enExample)
CZ (1) CZ165693A3 (enExample)
DE (1) DE69208868T2 (enExample)
DK (1) DK0571471T3 (enExample)
ES (1) ES2084347T3 (enExample)
FI (1) FI933551L (enExample)
GR (1) GR3019778T3 (enExample)
HU (1) HUT65766A (enExample)
IE (1) IE920442A1 (enExample)
IL (1) IL100888A0 (enExample)
MX (1) MX9200569A (enExample)
MY (1) MY131298A (enExample)
NO (1) NO932859L (enExample)
NZ (1) NZ241584A (enExample)
PT (1) PT100114A (enExample)
TW (1) TW263508B (enExample)
WO (1) WO1992013856A1 (enExample)
YU (1) YU13792A (enExample)
ZA (1) ZA92969B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (enExample) * 1992-03-05 1996-10-11 Pfizer
SK280193B6 (sk) * 1992-04-07 1999-09-10 Pfizer Inc. Indolové deriváty predstavujúce 5-ht1 agonisty, fa
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
AU694226B2 (en) * 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
ES2161892T3 (es) * 1994-06-01 2001-12-16 Astrazeneca Ab Derivados de indol como profarmacos de agonistas de los receptores afines a 5-ht1.
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
MX9706969A (es) * 1995-03-20 1997-11-29 Lilly Co Eli 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
US5942536A (en) * 1995-10-10 1999-08-24 Eli Lilly And Company N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DK1068198T3 (da) * 1998-03-09 2003-09-22 Lundbeck & Co As H 5-Heteroarylsubstituerede indoler
AU4831899A (en) 1998-06-30 2000-01-17 Eli Lilly And Company 5-HT1F agonists
WO2000063203A1 (en) * 1999-04-21 2000-10-26 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-ht6 affinity
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
AU2001296193B2 (en) 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
AU2003237599B2 (en) 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
SI1883451T1 (sl) 2005-04-13 2011-04-29 Neuraxon Inc Substituirane indolne spojine z NOS inhibitorno aktivnostjo
NZ588971A (en) * 2005-07-29 2012-06-29 4Sc Discovery Gmbh Novel heterocyclic NF-kappaB inhibitors
CA2637531A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
EP2010527B1 (en) 2006-04-13 2013-08-14 Neuraxon Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
WO2008021851A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
BRPI0820632A2 (pt) 2007-11-16 2015-06-16 Neuraxon Inc Compostos de indol e métodos para tratamento de dor visceral
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
CA2871514C (en) 2012-05-08 2020-08-25 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ror.gamma.activity and the treatment of disease
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2016179343A1 (en) 2015-05-05 2016-11-10 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
EP3368539B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Substituted indazole compounds as ror gamma t inhibitors and uses thereof
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
US4833153A (en) * 1985-11-08 1989-05-23 Glaxo Group Limited Indole derivatives
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
DE19775091I2 (de) * 1990-06-07 2007-05-24 Astrazeneca Ab Therapeutische heterocyclische Verbindungen

Also Published As

Publication number Publication date
WO1992013856A1 (en) 1992-08-20
CZ165693A3 (en) 1994-05-18
FI933551A7 (fi) 1993-08-11
JPH06500122A (ja) 1994-01-06
NO932859D0 (no) 1993-08-11
JPH07121942B2 (ja) 1995-12-25
ES2084347T3 (es) 1996-05-01
HU9302328D0 (en) 1993-10-28
YU13792A (sh) 1994-11-15
IL100888A0 (en) 1992-11-15
EP0571471A1 (en) 1993-12-01
MY131298A (en) 2007-08-30
MX9200569A (es) 1992-08-01
PT100114A (pt) 1993-05-31
AU1263792A (en) 1992-09-07
DK0571471T3 (da) 1996-04-01
ZA92969B (en) 1993-08-11
FI933551A0 (fi) 1993-08-11
NZ241584A (en) 1994-12-22
ATE135005T1 (de) 1996-03-15
CA2101521A1 (en) 1992-08-13
IE920442A1 (en) 1992-08-12
NO932859L (no) 1993-08-11
FI933551L (fi) 1993-08-11
DE69208868D1 (de) 1996-04-11
EP0571471B1 (en) 1996-03-06
AU655456B2 (en) 1994-12-22
DE69208868T2 (de) 1996-10-17
GR3019778T3 (en) 1996-07-31
KR930703305A (ko) 1993-11-29
TW263508B (enExample) 1995-11-21

Similar Documents

Publication Publication Date Title
HUT65766A (en) Process for preparing 5-heteroyl-indole derivatives and pharmaceutical compositions containing them
US5409941A (en) 5-heteroyl indole derivatives
JP4171417B2 (ja) ジペプチジルペプチダーゼｉｖインヒビターとしてのｎ−置換ピロリジン誘導体
US6620831B2 (en) Indazoles substituted with 1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
CN1187330C (zh) 吲哚衍生物、制备它们的方法、含有它们的药用组合物和它们的医疗应用
CN1832927A (zh) 新型γ－分泌酶抑制剂
CN1777602A (zh) 作为5－羟基色胺－6配体的杂环基－3－磺酰基氮杂吲哚或－氮杂吲唑衍生物
WO2000071120A1 (en) Antibacterial compounds
CN1826319A (zh) 芳基杂芳族化合物、含有它们的组合物及其用途
HU211630A9 (en) Thiazolylbenzofuran derivatives and pharmaceutical composition comprising the same
CA2195850A1 (en) Substituted indoles
JP2003507473A (ja) テロメラーゼインヒビターおよびその使用の方法
JP2599557B2 (ja) ４−置換１，２，４−トリアゾール誘導体
HU219489B (hu) Indolszármazékok, ezeket hatóanyagként tartalmazó gyógyszerészeti készítmények és eljárás előállításukra
HU217590B (hu) Eljárás 6-os helyen heterociklusos csoporttal helyettesített 4-amino-1,3,4,5-tetrahidro-benz[c,d]indolok és a vegyületeket tartalmazó gyógyszerkészítmények előállítására
CN1263746C (zh) 哒嗪酮衍生物
JP2004196678A (ja) ピラゾール系誘導体
HUT74866A (en) Thioindole pyperidinyl derivatives and pharmaceutical compositions containing them with antalgic properties
HUT59923A (en) Process for producing 4-substituted-dihydropyrido /4,3-d/pyrimidine derivatives and pharmaceutical compositions containing them as active components
WO1999010344A1 (fr) Derives d&#39;indole comme agonistes de 5-ht1b et 5-ht1d
US20090306144A1 (en) Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
JPH07505649A (ja) ヘテロ芳香族５−ヒドロキシトリプタミンレセプターアゴニスト
US5086052A (en) Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity
AU2005240843B2 (en) Piperazine derivatives of alkyl oxindoles
EP2201007A1 (fr) Derives de 4-phenyl-l, 3-thiazoles et de 4-phenyl-1, 3-oxazoles comme ligands des recepteurs cannabinoides

Legal Events

Date Code Title Description
DFD9 Temporary protection cancelled due to non-payment of fee